WATERTOWN, MA – September 26, 2026 (STL.News) Disc Medicine Inc. (NASDAQ: IRON) is facing continued scrutiny from multiple securities law firms over disclosures surrounding bitopertin, its experimental treatment for erythropoietic protoporphyria, after the U.S. Food and Drug Administration declined to approve the company’s application earlier this year and requested additional clinical evidence. Rosen Law Firm issued another investor notice Saturday, Sept. 26, saying it continues to investigate potential securities claims on behalf of Disc Medicine shareholders. Rosen alleges the biotechnology company may have issued materially misleading business information to investors and says it is preparing a prospective class action
Source: Read Original Article